MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

SmartCardia’s platform combines medical wearable technology with Artificial Intelligence to provide unique insights into patient’s health. They have developed SmartNeuralNet, a world-leading machine learning technology that powers their medical wearables. Their mission is to empower the millions of patients with chronic conditions with actionable insights to improve their health.

Nurami Medical focuses on creating advanced surgical scaffolds aimed at enhancing the repair and regeneration of soft tissues following internal surgeries. Utilizing electrospinning technology, the company develops biomaterials and nanofiber-based matrices that improve patient outcomes in various surgical procedures. These matrices feature a porous scaffold that promotes tissue regeneration and incorporate a novel temperature-sensitive sealant designed to prevent pathogen entry and cerebrospinal fluid leaks. This innovative approach addresses critical needs in surgical treatment, providing surgeons with effective solutions for their patients.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

SanaHeal is a company focused on developing innovative bioadhesive biomaterials, including tapes, pastes, and powders, designed to bind tissues or organs. Its bioadhesive tapes serve as an alternative to traditional sutures, promoting healing while reducing complications following surgery. This technology aims to transform the treatment of wounds and bleeding, enhancing patient outcomes. Additionally, SanaHeal's platform offers mechanical integration solutions that assist in the care of patients with multiple traumatic injuries, ensuring they receive the necessary intensive care.

Solenic Medical, a medical device company that develops a non-invasive treatment for infected metallic implants in the body. The company leverages the properties of alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries, such as knee and hip replacements, as well as in trauma-related implants such as plates and rods. Its AMF technology has the potential to completely replace the very expensive and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Rajiv Chopra and David Greenberg founded it in College Station, Texas in 2019.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.

HealthTech Connex Inc. is a brain technology company situated in the Health and Technology District, dedicated to advancing innovations in translational neuroscience aimed at enhancing health outcomes, particularly in neurological performance. The company focuses on brain vitality and develops technology that assesses cognitive brain health across multiple conditions, including brain injuries and neurological diseases. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex enables mental health professionals to identify cognitive impairments early, thereby improving care in both clinical and community settings worldwide.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

REMEDI is a solution provider for radiotherapy and radiography.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back their bodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology.

EndoVision Limited, founded in 2018 and based in Hong Kong, specializes in the development of artificial intelligence software designed for computer-aided diagnosis in endoscopy. The company's innovative technology aims to enhance the accuracy and efficiency of medical diagnoses during endoscopic procedures, providing healthcare professionals with advanced tools to improve patient outcomes.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

VinBrain is an artificial intelligence-focused company for health care. They artificial intelligence into medicine and medical image diagnostic. They provide DrAidTM Teleradiology, a remote medical imaging solution, connecting resources and expertise between hospitals to provide patients with quality diagnostic imaging services, anywhere, anytime.

ATDev specializes in assistive technology and medical device solutions, focusing on the development of innovative mobility devices. These devices are designed to enhance physical therapy accessibility for patients in the United States and globally. By integrating robotics into their solutions, ATDev aims to transform traditional physical therapy practices, facilitating improved patient outcomes and enabling healthcare providers to overcome challenges related to care delivery. Their technology specifically addresses the needs of individuals recovering from knee surgery, thereby enhancing the quality of care and support during rehabilitation.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Nanotis is a company which Solve various problems in infectious disease tests such as influenza.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

INIA Biosciences focuses on creating non-invasive medical devices that leverage sound wave technology to manage chronic inflammatory diseases. The company's innovative system combines biomarker monitoring with an ultrasound stimulator, aimed at reducing inflammation associated with transplant rejection and decreasing reliance on immunosuppressant medications. This home-administered, closed-loop monitoring system provides physicians with advanced diagnostic capabilities to improve the treatment and prevention of organ failure, ultimately enhancing patient care in chronic disease management.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

Fasciotens GmbH is a medical technology company based in Essen, Germany, founded in 2016. The company specializes in developing innovative devices for open abdomen therapy, which is crucial in treating severe infections, postoperative complications, and injuries that necessitate leaving the abdomen open. This therapy can be life-saving, particularly in cases such as abdominal compartment syndrome. Fasciotens' approach involves a unique method that maintains tension in the abdominal wall while increasing intra-abdominal volume. This technique combines the principles of mesh-mediated traction with those of an external fixator, ultimately enhancing the likelihood of successful outcomes for critically ill patients. Through its advanced solutions, Fasciotens aims to improve medical care in challenging surgical situations involving the open abdomen.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Surgical Automations focuses on the development of surgical robots and automation technologies aimed at improving patient safety and reducing medical errors. Their offerings include an AI-driven autonomous robotic navigation system tailored for endoscopic diagnostic and interventional procedures. A key innovation is their automated endotracheal intubation system, which accurately identifies the trachea's opening and facilitates the insertion of the endotracheal tube. This technology is designed to enhance surgical precision and minimize risks during medical procedures.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

FemTherapeutics Inc. is a Montreal-based medical device company with a mission to personalize therapeutics in women’s health. FemTherapeutics has developed an artificial intelligence platform that leverages patient data to design novel medical devices, and offer customization to achieve better clinical outcomes. Our first product involves the customization of gynecological prosthetics (or vaginal pessaries) to improve the management of Pelvic Floor Disorders in women.

The Shape Sensing Company specializes in advanced fiber optic 3D guidance systems that enable physicians to navigate medical devices within three-dimensional, patient-specific anatomical models. This technology is particularly beneficial in endovascular procedures, which traditionally depend on X-ray imaging for device guidance. By utilizing the company's proprietary 3D guidance workstation and guidewire, vascular surgeons and interventional radiologists can potentially reduce procedure times, lower operational costs, and enhance patient outcomes in the millions of vascular procedures performed annually in the United States. Additionally, the company collaborates with several original equipment manufacturer (OEM) partners to develop various 3D guided devices, which broadens the reach of its technology and maximizes revenue opportunities. Beyond the medical field, the company’s sensing technology has applications in industries such as aerospace, civil engineering, mining, and energy, providing significant feedback on the location and guidance of surgical tools and offering alternatives to harmful imaging methods.

CancerFree Biotech is a start-up focused on personalized cancer treatment through innovative technologies. The company utilizes circulating tumor cell culture to create organoid systems, which assist healthcare professionals in devising optimal treatment strategies for patients at all stages of cancer. By employing advanced bionic tumor organoid culture systems, CancerFree Biotech aims to minimize the likelihood of ineffective drug use. Their proprietary technology platform, E.V.A., combines organoid culture systems with AI image recognition to efficiently expand circulating tumor cells into cancer-derived organoids for various applications in cancer research, including cell therapy, vaccine development, and new drug discovery. This approach not only enhances the testing of anti-cancer drugs but also alleviates the burden of frequent testing for patients undergoing treatment.

Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained experts, focuses on enhancing healthcare access for underserved populations, particularly in rural areas where healthcare resources are limited. The company has developed a telerobotic ultrasound system that allows specialists to conduct diagnostic ultrasound procedures remotely, addressing the issue of specialists being predominantly located in urban centers. This innovative platform aims to improve patient access to timely care, enhance health outcomes, and provide financial benefits to hospitals by reducing costs and increasing revenue. By leveraging technology, Dopl seeks to bridge the gap in healthcare availability and ensure that quality medical services reach those who need them most.

DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.

Niramai Health Analytix Private Limited is a Bengaluru-based company founded in 2016 that specializes in cancer screening solutions. Its primary product, Thermalytix, is a software that utilizes machine intelligence to analyze thermography images, enabling early detection of breast cancer. This innovative approach allows for the identification of tumors significantly smaller than those detectable by traditional methods, making it a critical tool for improving survival rates. Niramai’s offerings include a compact screening device for specialty hospitals, a handheld device for independent medical practitioners with real-time cloud-based diagnostics, and a portable solution suitable for large-scale screenings. The technology is designed to be cost-effective, non-invasive, painless, and free of radiation, allowing women across all age groups to undergo frequent screenings with minimal human supervision and side effects.

KA Imaging Inc. is a Canadian company based in Waterloo that focuses on designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. Founded in 2015, the company has developed the world's first portable dual energy subtraction X-ray detector, which enhances the sensitivity of disease identification, including conditions such as pneumonia and fractures. This innovative device, known as Reveal, has received FDA clearance and is sold globally. KA Imaging offers a range of products, including static detectors for identifying faults in infrastructure, dual-energy detectors for baggage screening, dynamic detectors for inspecting moving parts, and specialized mammography detectors. With a team of 20 full-time and 10 part-time employees, the company holds 52 global patents and 17 issued US patents, emphasizing its commitment to advancing X-ray imaging technology across various sectors.

INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently advancing two key products: a closed-loop sacral neuromodulation system aimed at treating overactive bladder and a closed-loop brain neuromodulation device designed for epilepsy management. INOPASE's platform utilizes advanced algorithms to deliver personalized treatment plans by detecting symptoms and providing targeted stimulation therapy, positioning the company as a significant player in the treatment of chronic neurological diseases.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Qritive is a developer of an AI-powered diagnostic platform that assists medical professionals in analyzing microscopy images and patient data. The platform leverages artificial intelligence and natural language processing to streamline the analysis process, enhancing the efficiency of cancer diagnoses. By providing modern automated tools, Qritive aims to reduce the time and costs associated with cancer diagnosis, ultimately improving healthcare outcomes for patients. The company's innovative approach addresses the challenges faced by doctors in interpreting complex medical information, facilitating quicker and more accurate diagnoses.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Ligence is a Deep Tech startup based in Lithuania, specializing in healthcare solutions developed by a team of medical doctors proficient in artificial intelligence. The company focuses on automating heart ultrasound image analysis through its flagship product, Ligence Heart. This technology employs deep learning algorithms to accurately recognize various heart image views and perform essential measurements automatically. By streamlining the analysis process, Ligence Heart allows physicians to bypass manual measurements, enabling cardiologists and sonographers to enhance efficiency and significantly reduce analysis time, thereby allowing them to concentrate more on patient care and treatment.

Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess pre-drug/post-drug effects on a composite of heart attack, stroke and cardiac death.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

Artificial intelligence driven software applications for digital health technologies. We train multimodal systems to be able to execute automated administration optimisation tasks as well as repetitive patient monitoring and classification solutions. We work closely with the NHS.

IFPx is a company focused on developing innovative patient monitoring technology aimed at improving the management of chronic illnesses, specifically heart failure. Its platform features advanced sensors that measure interstitial fluid pressure, allowing healthcare professionals to directly analyze fluid buildup in patients. This technology aims to enhance the monitoring and treatment of heart conditions, ultimately transforming patient care and outcomes in this critical area of healthcare.

Newrotex is an Oxford-based SME that has developed an off-the-shelf silk-based conduit for the repair of peripheral nerve injuries with IP granted.

StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostics aimed at identifying high-risk markers for stomach cancer. The company utilizes next-generation technology and precision immunology to create tests that exceed the capabilities of current antibody screenings, offering enhanced precision and more comprehensive disease information. By improving diagnostic accuracy, Biotome seeks to equip medical professionals with the tools necessary to provide better treatment options for patients, ultimately benefiting healthcare outcomes globally.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

PanTher Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative drug-delivery treatments for cancer. The company has created a proprietary platform that enables targeted and sustained drug administration directly at tumor sites, significantly enhancing therapeutic efficacy while minimizing the toxic side effects commonly associated with traditional chemotherapy. This approach allows oncologists to unlock the full potential of cancer drugs, particularly in challenging cases such as pancreatic cancer, where treatment options can be limited. Founded in 2014, PanTher Therapeutics aims to improve cancer care by addressing the needs of patients suffering from life-threatening malignancies.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

Xtremedy Medical is a medical technology based at NUI Galway that manufactures surgical devices to treat bone and deep tissue infections by sending electrical signals through wounds, both on the surface and below, to eliminate any residual infection.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

ImmersiveTouch, Inc. is a medical technology company based in Chicago, Illinois, specializing in virtual reality simulators for medical training and patient engagement. Established in 2005, the company develops applications for surgical education and pre-operative planning, utilizing its advanced Ikshana XR platform. This platform employs proprietary software and artificial intelligence to convert radiology scans into 3D simulations, allowing for detailed anatomical exploration and informed surgical decision-making. ImmersiveTouch's surgical simulators feature an immersive pod where surgeons interact with realistic 3D models, experiencing high visual acuity and realistic sensory feedback. The training modules cover various specialties, including core surgical skills, neurosurgery, orthopedic surgery, spine, and ophthalmology. By providing actionable insights, ImmersiveTouch aims to improve patient outcomes, reduce complications, and enhance the efficiency of surgical procedures.

Covellus is a medical device company that is developing a unique Platform Technology for creating medical device catheters.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

Universal Brain is focused on creating individualized treatments for mental health by utilizing advanced neurofeedback therapy methods. The company engages in research and development of algorithms that integrate data from electroencephalograms (EEG) and magnetic resonance imaging (MRI) through deep learning techniques. This approach allows for the design and manufacturing of portable electroencephalograph headsets, enhancing the capabilities of mental health professionals in diagnosing and treating psychiatric conditions. By analyzing brain data, Universal Brain aims to provide valuable insights that improve the effectiveness of psychiatric care.

Happitech is a pioneering company that offers a CE Certified heart rate software development kit (SDK) for Android and iOS, facilitating remote patient management through mobile applications. By integrating Happitech's algorithms, users can monitor vital signs, including heart rate and heart rate variability, utilizing only a smartphone camera. The technology is backed by clinical evidence and powered by AI, making it suitable for various applications such as cardiovascular screening, stroke prevention, and telehealth services. Happitech's solutions are designed to enhance care management, support health practitioners, and empower patients globally. The company has received multiple accolades, including recognition as one of the top Dutch COVID-19 healthcare companies and awards for its innovative contributions to digital health.

Adcura, Inc. is a medical device company specializing in minimally invasive implant products aimed at enhancing the quality of life for patients with spine-related conditions. The company develops a range of innovative products, including retractors, disposable accessories, and adjustable lumbar fusion devices, which are designed to address existing surgical inefficiencies. By focusing on precision technologies and surgical techniques, Adcura enables medical practitioners to improve surgical outcomes while reducing post-operative complications for patients.

Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

Hypervision Surgical focuses on enhancing surgical precision, safety, and efficiency through its innovative imaging technology. The company develops an advanced non-contact and non-invasive optical imaging system that employs hyperspectral imaging to analyze tissues during surgery. By splitting light into multiple spectral bands, the system provides real-time, data-driven tissue characterization, allowing clinicians to visualize and assess tissue without the need for contrast agents. This technology aims to improve surgical outcomes while minimizing risks to patients, positioning Hypervision Surgical at the forefront of AI-powered surgical assistance.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

INVENIO IMAGING, Inc. is a privately held corporation founded in 2012 based on the research of Prof. Sunney Xie of the Department of Chemistry and Chemical Biology at Harvard University. Invenio is dedicated to developing a fast, reliable, simple-to-use technology for non-destructive microscopic analysis of the molecular make-up of tissues and other materials. INVENIO’s platform technology is positioned to enter the R&D microscopy market, and it is developing instrumentation for several high-value medical applications. INVENIO IMAGING Inc. acknowledges funding from the NSF and NIH SBIR programs.

Knowtex provides savings in administrative work, streamlines organisational efficiency, ensures visits are billed at the appropriate level of service, and has personable conversations with patients. It helps create visit notes from medical conversations. For inquiries, an online inquiry form is available on their website.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company has created a novel device that activates the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to preserve brain tissue during critical moments. This approach not only delays brain damage but also provides healthcare providers with additional time to intervene effectively. Ultimately, NeuraStasis seeks to empower patients to leave the hospital without disabilities following a stroke, enhancing recovery outcomes and improving quality of life.

MACH32 is a medical device company focused on developing innovative drug delivery solutions to address significant healthcare challenges. The company specializes in creating medical devices designed for the pre-hospital treatment of trauma, producing reliable and functional tools that aim to save lives in urgent situations. Their technology includes novel drug-delivery systems that enable healthcare professionals to utilize protective equipment effectively, safeguarding them from infectious aerosols, particularly highlighted during the Covid-19 pandemic. By prioritizing safety and efficacy, MACH32 addresses critical needs in emergency medical care.

270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. It specializes in the development of the SurroundScope System, an innovative laparoscopic camera designed to enhance visualization during surgery. This system features a unique 270-degree wide field of view technology, which significantly reduces blind spots and the risk of off-screen injuries, thereby improving patient outcomes. The SurroundScope also addresses common issues faced during laparoscopic procedures, such as lens fogging and visual obstructions from surgical smoke. The system has received FDA clearance and has garnered endorsements from leading experts in the field, positioning 270Surgical as a key player in advancing surgical techniques.

Pumpinheart is a heart failure treatment system with preserved ejection fraction (HFpEF).

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

AMI Corp specializes in medical consulting and the development of medical devices, focusing on telehealth solutions. The company offers a range of telemedicine services, which include a unique stethoscope system designed for remote auscultation. This innovative technology allows for the transmission of heart sounds as both audible and visual data, facilitating better access to medical care for patients through telehealth initiatives. AMI Corp aims to enhance the delivery of healthcare services by leveraging advanced communication methods in the medical field.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

JuneBrain, LLC is a Washington, D.C.-based company founded in 2017 that focuses on developing wearable and non-invasive imaging devices for multiple sclerosis patients. The technology allows patients to monitor their disease activity from home, facilitating earlier detection of MS attacks and enhancing the monitoring of treatment efficacy. By leveraging telemedicine, JuneBrain aims to optimize remote assessment for neurological diseases, thereby enabling clinicians to track patients outside traditional clinical settings. The company's long-term vision includes extending its device's applications to a broader range of neurodegenerative diseases, promoting more accessible and frequent monitoring of brain health.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

Nininger Medical is focused on developing a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This innovative approach aims to provide effective treatment for heart failure, particularly in preventing structural heart issues. The company has recently received a Small Business Innovation Research grant from the National Science Foundation, underscoring its commitment to advancing medical technology in the field of cardiovascular care.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

Thermidas is a Finnish health technology company dedicated to developing and advancing infrared thermal imaging for diagnostic use.

CerebraAI is a digital diagnostic company focused on improving stroke diagnosis through advanced artificial intelligence technology. Since its inception in 2018, the company has developed CEREBRA, an AI-powered software that enhances the efficiency of CT machines. This software enables rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography, facilitating quicker and more accurate treatment for patients. By empowering community hospitals with these innovative tools, CerebraAI aims to optimize patient outcomes in neuroradiology and address the critical time sensitivity associated with stroke care.

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.